These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3309969)

  • 1. Uses and limitations of hormone, receptor and enzyme assays in prostate cancer.
    Martin PM; Le Goff JM; Brisset JM; Ojasoo T; Husson JM; Raynaud JP
    Prog Clin Biol Res; 1987; 243A():111-40. PubMed ID: 3309969
    [No Abstract]   [Full Text] [Related]  

  • 2. Punch biopsy tissue: enzyme and receptor analyses as criteria for hormone responsiveness in the treatment of prostatic cancer--limitations.
    Bartsch G; Janetschek G; Daxenbichler G; Dietze O; Mikuz G
    Prog Clin Biol Res; 1987; 243A():101-10. PubMed ID: 3658997
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hormonal receptors and other procedures for predicting clinical response in cancer of the prostate].
    Habib FK; Chisholm GD
    Arch Esp Urol; 1984 Dec; 37 Suppl 2():751-9. PubMed ID: 6085672
    [No Abstract]   [Full Text] [Related]  

  • 4. A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer.
    Barrack ER; Tindall DJ
    Prog Clin Biol Res; 1987; 239():155-87. PubMed ID: 3309954
    [No Abstract]   [Full Text] [Related]  

  • 5. [Importance of determining steroid hormone receptors and the treatment of prostatic cancer].
    Fedotov IA; Denisov LE; Kozlov VP; Degtiar' VG
    Urol Nefrol (Mosk); 1983; (1):63-70. PubMed ID: 6187115
    [No Abstract]   [Full Text] [Related]  

  • 6. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.
    Suzuki K; Nishiyama T; Hara N; Yamana K; Takahashi K; Labrie F
    Prostate Cancer Prostatic Dis; 2007; 10(3):301-6. PubMed ID: 17387321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor assays in advanced prostatic cancer.
    Buttyan R; Olsson CA
    Urol Clin North Am; 1984 May; 11(2):311-7. PubMed ID: 6375068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
    Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
    Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptor sites: genomic sites for androgenic regulation of prostatic growth.
    Rennie PS
    Prog Clin Biol Res; 1987; 239():189-203. PubMed ID: 3309955
    [No Abstract]   [Full Text] [Related]  

  • 10. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
    Wang LG; Mencher SK; McCarron JP; Ferrari AC
    Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid receptor and biochemical profiles in prostatic cancer: correlation with response to hormonal treatment.
    Barrack ER; Brendler CB; Walsh PC
    Prog Clin Biol Res; 1987; 243A():79-97. PubMed ID: 3309976
    [No Abstract]   [Full Text] [Related]  

  • 12. In situ androgen producing enzymes in human prostate cancer.
    Nakamura Y; Suzuki T; Nakabayashi M; Endoh M; Sakamoto K; Mikami Y; Moriya T; Ito A; Takahashi S; Yamada S; Arai Y; Sasano H
    Endocr Relat Cancer; 2005 Mar; 12(1):101-7. PubMed ID: 15788642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.
    Culig Z; Stober J; Gast A; Peterziel H; Hobisch A; Radmayr C; Hittmair A; Bartsch G; Cato AC; Klocker H
    Cancer Detect Prev; 1996; 20(1):68-75. PubMed ID: 8907206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytoplasmic androgen and estrogen receptor content in the tissues of human prostatic cancer].
    Kushlinskiĭ NE; Bassalyk LS; Matveeva BP; Gorilovskiĭ LM; Degtiar' VG
    Urol Nefrol (Mosk); 1984; (4):41-6. PubMed ID: 6474626
    [No Abstract]   [Full Text] [Related]  

  • 15. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN; Schröder FH
    BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human prostate cancer (PC-82) in nude mice: a model to study androgen regulated tumor growth.
    van Steenbrugge GJ; Groen M; Bolt-de Vries J; Romijn JC; Schroeder FH
    Prog Clin Biol Res; 1985; 185A():23-50. PubMed ID: 4034577
    [No Abstract]   [Full Text] [Related]  

  • 18. The androgen receptor and mechanisms for androgen independence in prostate cancer.
    Javidan J; Deitch AD; Shi XB; de Vere White RW
    Cancer Invest; 2005; 23(6):520-8. PubMed ID: 16203660
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predictive value of the determination of receptors in carcinoma of the prostate].
    Castellanos JM; Galán A; Calvo MA; Schwartz S
    Rev Esp Oncol; 1984; 31(2):265-77. PubMed ID: 6085864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.